Analysts expect Haemonetics to report consensus revenue of $345.15 million and adjusted EPS of $1.29, with the stock currently trading near $120.14, slightly above the average analyst price target of $120.00.
Investors are primarily focused on the performance of the MedSurg segment and the continued rollout of the NexSys Plasma collection system.
Following a strong fiscal first quarter where the company raised its full-year organic revenue guidance to 4-7%, markets are looking for sustained momentum in the Interventional Technologies business, particularly the VASCADE vascular closure product line.
Management's ability to maintain adjusted operating margins despite higher personnel and freight costs remains a key focal point for the report.